高和血管:临床外体序列测序可以重新定义范式吗?
Marina Tarsitano1, Maurizio Russo2, Vincenzo Andreone3
1UOC Medical Genetics, AORN A. Cardarelli, 80131 Naples, Italy.
Life (Basel, Switzerland)
|February 27, 2026
概括
在中风患者中,阿尔特酶诱导的血管与多种遗传变异有关,而不是单一的基因. 这些变异相互作用,通过"上下文致病性"增加风险,以获得更安全的治疗决策.
科学领域:
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 重组组织型等离子体激活剂 (tPA) 对于急性缺血性中风治疗至关重要.
- 血管,tPA的严重副作用,与布拉迪基宁信号传递有关.
- 与tPA相关的血管的遗传基础尚不清楚.
研究的目的:
- 调查假设阿尔特酶相关的血管是多基因敏感性表型的假设.
- 为了确定在接受高高的患者中导致血管风险的遗传变异.
- 探索系统级遗传框架,以了解药物不良反应.
主要方法:
- 临床外体序列测序在11名患者进行,这些患者在高高施用后经历了血管.
- 在相互作用的生理系统中分析了遗传变异,包括布拉迪基宁调节,内皮功能和信号通路.
- 通过通路信息的多基因方法来解释变异的意义.
主要成果:
- 没有单一的致病变体被确定;相反,观察到不同的遗传脆弱性模式.
- 患者表现出重叠的遗传倾向,影响布拉迪基宁调节,内皮结构,神经血管信号和血管修复.
- 不确定意义的个别变异共同导致了系统层面的脆弱性,称为"上下文病原性".
结论:
- 严重的高高酶相关性血管炎是由相互作用的遗传网络造成的,而不是单一的基因.
- 系统层面的遗传视角对于解释药物不良反应至关重要.
- 多基因风险分层框架可以增强个性化的血栓解压疗法和患者安全.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:11Genome-wide Association Studies-GWAS
16.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.0K